Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-27 16:35:24 - browse：23

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： FDA clears AI tool for detecting skin cancer

hotspot

WSS

FDA clears AI tool for detecting skin cancer

Elizabeth Holmes banned from government health programs

My yearlong odyssey to get my son’s ADHD medication covered

Senators push IRS to launch nonprofit hospital probe

Francis Collins on trust in science and how Covid communications failed

FDA clears AI tool for detecting skin cancer

Wikipedia

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

Dozens dead from Maui wildfires: What we know about the victims

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Anesthesiologist group: stop taking Ozempic before surgery

Health AI: on the border between health care and tech

Peter Hotez and the public health issue of online harassment

NIH director takes cautious approach to Biden drug pricing priority

DIEP, the 'gold standard' of breast reconstruction, is under threat

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

focus

AI generated plenty of interest at JPM but not a lot of trust

NIH director takes cautious approach to Biden drug pricing priority

Senators push IRS to launch nonprofit hospital probe

Montana youths win climate lawsuit against state for promoting fossil fuels

New brain studies show LSD's effects on the brain in full color

Copay coupons to count toward deductibles, after Biden court move

leisure time

leisure time

hotspot

explore